COVID-19 in a human T-cell lymphotropic virus type-1 carrier

Takatoshi Enomoto; Takayuki Shiroyama; Haruhiko Hirata; Saori Amiya; Yuichi Adachi; Takayuki Niitsu; Yoshimi Noda; Reina Hara; Kiyoharu Fukushima; Yasuhiko Suga; Kotaro Miyake; Shohei Koyama; Kota Iwahori; Izumi Nagatomo; Natsuko Tokuhira; Akinori Uchiyama; Yoshito Takeda; Atsushi Kumanogoh

doi:10.1002/ccr3.5463

COVID-19 in a human T-cell lymphotropic virus type-1 carrier

Clin Case Rep. 2022 Feb 15;10(2):e05463. doi: 10.1002/ccr3.5463. eCollection 2022 Feb.

Authors

Takatoshi Enomoto¹, Takayuki Shiroyama¹, Haruhiko Hirata¹, Saori Amiya¹, Yuichi Adachi¹, Takayuki Niitsu¹, Yoshimi Noda¹, Reina Hara¹, Kiyoharu Fukushima¹, Yasuhiko Suga¹, Kotaro Miyake¹, Shohei Koyama¹, Kota Iwahori¹, Izumi Nagatomo¹, Natsuko Tokuhira², Akinori Uchiyama², Yoshito Takeda¹, Atsushi Kumanogoh^{1

3

4

5}

Affiliations

¹ Department of Respiratory Medicine and Clinical Immunology Osaka University Graduate School of Medicine Osaka Japan.
² Department of Anesthesiology and Intensive Care Medicine Osaka University Graduate School of Medicine Osaka Japan.
³ Department of Immunopathology, WPI, Immunology Frontier Research Center (iFReC) Osaka University Osaka Japan.
⁴ Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI) Osaka University Osaka Japan.
⁵ Center for Infectious Disease for Education and Research (CiDER) Osaka University Osaka Japan.

Abstract

This is the first report of COVID-19 in a human T-cell lymphotropic virus type-1 (HTLV-1) carrier. HTLV-1 infection can cause immune dysfunction even in asymptomatic carriers. This case highlights the need for guidance on management of COVID-19-HTLV-1 coinfection, specifically on the appropriate use of corticosteroid treatment while considering secondary infection.

Keywords: COVID‐19; SARS‐CoV‐2; coinfection; human T‐cell lymphotropic virus type‐1.

Publication types

Case Reports